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1. Introduction  
Congenital malformations contribute to a significant proportion of infant morbidity and 
remain a leading cause of death in both the neonatal and postneonatal periods (Brunner and 
van Driel, 2004). Despite the high frequency of these disorders, their underlying causes 
remain often obscure due to the complexity of human development. The human genome 
contains approximately 25,000 genes and most of them become active to build both tissue 
and body structures (Brunner and van Driel, 2004). Moreover, growth and morphogenesis 
of the human embryo relies on the precise orchestration and intercalation of multiple 
cellular functions, and the spatio/temporal control of the inherent molecular and biological 
processes. Therefore, modern human genetics regards the detailed understanding of genes 
and molecular strategies involved as "an indispensable investment" that can foster greater 
progress in the diagnosis and treatment of these human disorders.  
From the beginning of the last century, going back to the Spemann and Mangold 
experiments, cell to cell signalling has been recognized as one fundamental principle of 
animal development (Freeman and Gurdon, 2002). At almost every developmental stage 
cells communicate with each other and such processes permit the generation of cell-type 
differences during development and the coordination of cell functions during tissue/organ 
morphogenesis or tissue/organ homeostasis (Freeman and Gurdon, 2002; Pires-daSilva and 
Sommer, 2003).  
Chemical communication is by far the major form of information transfer between cells. 
Following release by instructive cells, signals move towards target cells through either direct 
contact or by short and long diffusion (Freeman and Gurdon, 2002; Papin et al., 2005). On 
target cells signals are captured by distinct cellular receptors that upon integrating and 
interpreting them activate appropriate intracellular signalling pathways and effectors to 
modify cell fate, metabolism or function (Freeman and Gurdon, 2002; Pires-daSilva and 
Sommer, 2003).  
Research in the past two decades has yielded important advances towards the identification 
of the signal proteins, receptors, and intracellular proteins involved in signalling processes. 
For example the human genome contains more than 1500 genes that encode receptor 
www.intechopen.com
 
Congenital Anomalies  Case Studies and Mechanisms 
 
20
proteins, and the number of different receptor proteins is further increased by alternative 
RNA splicing and post-translational modifications. Surprisingly, genetic and biochemical 
studies revealed that only a few different classes of signalling pathways mediate patterning 
of a wide variety of cells, tissues and organs. For example, Fibroblast growth factors (FGF) 
Hedgehog (Hh), Wingless related (Wnt), Transforming growth factor-b (TGF-b) and Notch 
are used reiteratively during development to mediate very different biological processes in 
different animals (Freeman and Gurdon, 2002; Pires-daSilva and Sommer, 2003). In other 
words, a signal that in one instance will cause a cell to differentiate terminally will 
elsewhere lead another cell type to undergo mitosis and in a third context will trigger cell 
death.  
These findings have raised the question of how generic signals can trigger tissue-specific 
responses. As a general principle specificity relies on the repertoire of receptors and 
intracellular mediators that are active in a given cell at a given time (Freeman and Gurdon, 
2002). Nevertheless, there is now clear evidence that specificity of signal outcome is also the 
product of biological strategies ensuring signal level, strength, duration and its spatio-
temporal distribution (Freeman and Gurdon, 2002). For example, several of these signalling 
molecules function as morphogens that form concentration gradients across developmental 
fields and specify different cell fates in a concentration dependent fashion during pattern 
formation (Freeman and Gurdon, 2002). Other studies have also shown that differences in 
the kinetics of the ligand or receptor binding mode, and changes in the temporal and 
quantitative supply of active ligand can contribute to increases in the heterogeneity of 
biological responses to incoming signals, but without losing the cell specific effects that 
ensure reproducibility of developmental processes (Freeman and Gurdon, 2002).  
In the pursuit of molecular mechanisms that underlie these further layers of regulation 
attention has progressively shifted towards components of the extracellular matrix. Besides 
being structural scaffolds, these proteins are now evaluated as vital elements of the cell 
signalling machinery that provide processing and bioavalaibility of instructive signals 
(Bernfield et al., 1999; Bulow and Hobert, 2006). 
In particular, cell surface proteoglycans such as  Glypicans (Gpcs) interact with chemokines, 
growth factors/morphogens and their receptors (Bulow and Hobert, 2006; Hacker et al., 
2005; Nybakken and Perrimon, 2002). Disruption of Gpc functions in Drosophila, Zebrafish, 
Xenopus Laevis and mouse results in phenotypes reminiscent of defects in cellular responses 
to regulatory signalling molecules (Hacker et al., 2005; Lin, 2004). Yet, genetic and 
embryological studies link Gpcs to the regulation of cell signalling events during 
morphogenesis and adult physiology (Bishop et al., 2007; DeBaun et al., 2001; Hacker et al., 
2005; Lin et al., 1999). In humans, mutations in the Gpc-3 gene are associated with several 
diseases. For example, mutations in the Gpc-3 gene underlie a condition called Simpson-
Golabi-Behmel syndrome, which is characterized by overgrowth of the body and other birth 
defects (DeBaun et al., 2001). Homozygosity for null mutations in the Gpc-6 gene cause 
autosomal recessive omodysplasia, a genetic condition characterized by severe short stature 
and congenital heart defects (Campos-Xavier et al., 2009). Additionally, increased and 
decreased activity of some Gpcs (including Gpc-1, -3, -4 and -6) occurs in certain forms of 
cancer (Filmus, 2001). Here, we review our current knowledge on the implication of these 
proteoglycans in congenital malformations, and discuss our understanding of their 
mechanism of action. 
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2. Molecular design of cell surface glypicans 
The name “glypicans” identifies a family of heparan sulphate proteoglycans (HSPGs) that 
are linked to the exocytoplasmic surface of the plasma membrane through a covalent 
glycosyl-phosphatidylinositol (GPI) linkage (Bulow and Hobert, 2006). Together with 
Syndecans, gpc gene products are the major cell surface HSPGs (Bulow and Hobert, 2006). 
Gpcs have been highly conserved throughout evolution and most likely arose early during 
metazoan evolution (Filmus et al., 2008). In this section, we describe their major structural 
features that have been crucial to elucidate their in vivo roles. 
2.1 Glypican assembly 
Gpcs are proteins of around 60–70 kDa with a characteristic pattern of 14-conserved cysteine 
residues mainly located to the central domain (De Cat and David, 2001). Gpcs also share an 
N-terminal signal sequence and a hydrophobic C-terminal sequence involved in the 
formation of the GPI anchor structure (Fig. 1; De Cat and David, 2001). Heparan sulphate 
glycosaminoglycan (HSGAG) polysaccharide side chains can be attached to serine residues 
in consensus sequences, such as XGlyXGlySerX, that are located between the central domain 
and the C-terminal GPI-anchor (De Cat and David, 2001). The HSGAG of proteoglycans can 
undergo complex patterns of modification consisting of sulphations of hydroxyl groups in 
individual sugar molecules, epimerizations of specific carbon atoms and changes in length 
of the individual sugar residues (Bulow and Hobert, 2006; Nybakken and Perrimon, 2002). 
Such modifications are thought to generate a large structural diversity that might encode 
information for the selective binding of protein ligands (Bulow and Hobert, 2006; Nybakken 
and Perrimon, 2002). In general, Gpcs carry these HS chains, but Gpc5 also displays 
chondroitin sulfate modifications (Saunders et al., 1997). 
  
Fig. 1. Schematic representation of the Gpc structure.  
The glypican core protein spans the extracellular space. Disulfide bridge (S-S) are thought to 
organize the core protein as a compact globular domain. HS chains are covalently bound to 
serine residues that are part of X-Gly-X-Gly-Ser-X motifs in the polypeptide chain close to 
the plasma membrane. The carboxyterminus of Gpcs is covalently linked to the plasma 
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membrane via a GPI anchor. Red filled hexagon chains represent HS chains. S = serine; G = 
glycine; X = aminoacid (adapted from De Cat, B. and David, G., 2001). 
Proteolytic cleavages of the core proteins can also contribute to generate distinct Gpc forms. 
As shown for several vertebrate and invertebrate proteins, the N-terminal cysteine-rich 
domain of Gpcs can be splitted from the HS-modified and GPI-anchored C-terminal domain 
following endo-proteolytic processing (Song and Filmus, 2002). To which extent this event 
occurs in physiological condition is matter of investigation because the ratio between 
uncleaved and cleaved Gpcs varies according to the gpc family member and the tissue-
specific context. The N-terminal Gpc fragment is not membrane-associated and, once 
generated, it can remains linked to its C-terminal half through one or more disulfide bridges 
(De Cat et al., 2003; Eugster et al., 2007). Thus, proteolytic processing can provide a 
molecular strategy to rapidly make available a secreted Gpc product, if needed, as such a 
form could be released from producing cells simply following redox changes of the extra-
cellular environment. 
2.2 Evolutionary origins 
Gpcs are evolutionarily conserved proteins found in organisms as distinct as nematodes, 
fruit flies and mammals (De Cat and David, 2001; Fico et al., 2007; Filmus et al., 2008). The 
human and mouse genome contain six Gpc family members, Gpc-1 to Gpc-6 in humans and 
gpc-1 to gpc-6 in mice (De Cat and David, 2001; Fico et al., 2007; Filmus et al., 2008) whereas 
five gpc-like genes have been identified in zebrafish (Filmus et al., 2008; Topczewski et al., 
2001), two in Drosophila (dally and dally-like; Baeg et al., 2001; Nakato et al., 1995) and two in 
C. elegans (gpn-1 and lon-2; Gumienny et al., 2007; Hudson et al., 2006). The amino acid 
sequences of mammalian Gpc vary from being 17% to 63% identical. However, sequence 
relationships and exon organizations suggest that mammalian gpcs consist of two distinct 
subfamilies (De Cat and David, 2001; Fico et al., 2007; Filmus et al., 2008). The first subfamily 
includes gpc-1, -2, -4 and -6 genes with amino acid sequence homology ranging from 40–60% 
and composed of nine exons. The other subfamily incorporates gpc-3 and -5, with amino 
acid sequences 40% identical and containing eight exons. Of note, gpc-6 maps near to gpc-5 
on mouse chromosome 14 and on human chromosome 13. Gpc-4, which is most homologous 
to gpc-6 maps to chromosome Xq26 near to gpc-3, which is highly related to gpc-5 (De Cat 
and David, 2001; Fico et al., 2007; Filmus et al., 2008). Therefore, members of the different 
subfamilies are inclined to cluster on the same chromosome. Whether gpc subfamilies and 
the genomic linkage of different members have evolved from a series of gene and genome 
duplications is still a matter of debate. In support of this possibility there are studies in 
organisms such as Drosophila and zebrafish showing the existence of distinct orthologs for 
each mammalian subfamily and their genomic linkage (Filmus and Capurro, 2008). It will be 
interesting to examine to what extent the appearance of gpc subfamilies might underlie the 
evolution of functional similarities in members of the same subfamily and functional 
differences among those more divergent. In this context, studies on Dally and Dally-like 
aimed at distinguish their activity on Hh have shown that Dally-like but not Dally is required 
for Hh response in a Drosophila cultured cell assay (Williams et al., 2010). Intriguingly, Gpc-4 
and -6, which are the mammalian Gpcs most closely related to Dally-like, complement Dally-
like function in this biological system (Williams et al., 2010). In contrast, Dally and its 
ortholog Gpc-3 exhibit trans-dominant negative activities (Williams et al., 2010). These 
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studies suggest a large trend in which related Gpc members may have evolved similar 
activities in distinct cellular contexts, but further understanding will come from studies on 
other signalling activities. 
3. Glypicans: From structural compounds to signalling molecules 
Once considered as acting merely as structural components of the extra cellular matrix, Gpcs 
are now widely recognized as essential modulator of many biological processes. These include 
their role as carriers in cellular uptake of growth promoting polyamines such as spermine 
(Casero and Marton, 2007; Fransson et al., 2004). It has been proposed that the binding of Gpcs 
to polyamines is mediated by electrostatic interactions occurring between Gpc HS side chains 
and polyamine residues. After transport to endosomes, HS moieties are degraded by nitric 
oxide. This is expected to weaken HS interaction with polyamines and results in their 
unloading and possibly exit from endosomes to elicit functions. The mechanisms underlying 
polyamines uptake has been analyzed in several systems and discussed in previous reports 
(Belting, 2003; Fransson et al., 2004).  
To date, Gpcs are also considered as potential carriers of cell-penetrating peptides. Cell-
penetrating peptides are short cationic peptides extensively studied in medicine as drug 
delivery agents for the treatment of different diseases including cancer and virus infection 
(Rajendran et al. , 2010). Their entry into cells is typically initiated through interaction with 
cell-surface HS proteoglycans (HSPGs) via electrostatic interactions, followed by 
endocytosis (Poon and Gariepy, 2007). Studies on the intracellular delivery of cell-
penetrating peptides have shown that the migration of these peptides into cells as well as 
their final destination could depend on the nature of the HSPGs expressed at the cell surface 
(Poon and Gariepy, 2007). The GPI-anchor typical of Gpc proteins provides them with 
specific membrane-trafficking properties distinct from those of transmembrane HS 
molecules such as Syndencans (Chatterjee and Mayor, 2001; Payne et al., 2007). Therefore, 
Gpcs mediated uptake of cell-penetrating peptide is currently evaluated as a new strategy to 
enhance target-specific delivery of a large variety of entrapped therapeutic drugs. 
Research on Gpcs has further increased due to the discovery that they act at the interface 
between the extra cellular environment and the inner cellular domain to fine tune inputs 
triggered by key secreted regulatory proteins. Although Gpcs have important physiological 
roles (Bishop et al., 2007), we concentrate here on their developmental functions and on the 
molecular mechanisms by which Gpcs trigger cell fate and tissue pattern.  
3.1 Glypicans as modulator of regulatory extra-cellular signals 
Our knowledge of Gpc biology has significantly expanded over the past decade with the 
discovery that Gpcs are not simply structural proteins. Being mostly extracellular, Gpcs are 
involved in the regulation of various signalling pathways triggered by secreted peptides 
including that of Wnt, Fgf, Hh, bone morphogenic protein (Bmp), insulin-like growth factor 
and hepatocyte growth factor (Fico et al., 2007; Filmus and Capurro, 2008).  
The functional relevance of Gpcs as signalling modulators has come from the genetic 
analysis and embryological manipulation of Gpcs in different species and in cultured cells 
(Table 1). 
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Core 
protein 
Species Major defect 
Affected 
Signals  
References 
Lon-2 C elegans Body length  Bmp Gumienny TL, Curr Biol 2007 
Dally 
Drosophila 
mutant 
Embryogenic 
epidermis 
 
Wing imaginal 
discs 
 
Eye-antennal 
discs 
 
Germline stem 
cells 
Hg, Wg 
 
Hg, Wg 
 
 
Dpp 
 
 
Bmp 
Nybakken K, Biochim Biophys 
Acta 2002 
Han C, Development 2004 
 
Nybakken K, Biochim Biophys 
Acta 2002 
Han C, Development 2004 
 
Hacker U, Nat Rev Mol Cell Biol 
2005 
Lin X, Development 2004 
 
Guo Z, Development 2009 
 
Dally-like 
Drosophila 
mutant 
Wing imaginal 
disc 
 
 
Tracheal 
morphogenesis  
Wg 
 
 
Fgf 
Nybakken K, Biochim Biophys 
Acta 2002 
Kreuger J, Dev Cell 2004 
Kirkpatrick CA, Dev Cell 2004 
 
Yan D, Dev Biol 2007 
Knypek 
Zebrafish 
mutant 
Gastrulation 
 
 
 
Cartilage/bone 
morphogenesis  
      Wnt 
 
 
 
Wnt 
Topczewski J, Dev Cell 2010; 
Caneparo L, Genes Dev 2007;  
Sepich DS, Development 2011 
 
LeClair EE, Dev Dyn 2009  
gpc4 
Xenopus 
morpholino 
Gastrulation 
Dorsal forebrain 
Wnt 
Fgf 
Song HH, J Biol Chem 2005 
Galli A, Development 2003 
gpc1 
Mouse 
null allele 
Early 
neurogenesis 
Fgf Jen YH, Neural Dev 2009 
gpc3 
Mouse 
null allele 
Body size 
 
Limb 
mesenchyme 
 
Ureteric 
mesenchyme  
Wnt 
 
Bmp 
 
Bmp, Fgf 
Song HH, J Biol Chem 2005 
 
Grisaru S, Dev Biol 2001 
 
Paine-Saunders S, Dev Biol 2000 
 
Table 1. Glypicans function in model organisms. This table reports the major phenotypes 
observed by genetic and embryological studies on glypican genes and the main involved 
signals 
For example, in vitro studies have shown that Gpc4 positively modulated hepatocyte 
growth factor activity during renal epithelial branching morphogenesis (Karihaloo et al., 
2004). Mice lacking Gpc3 are affected by overgrowth, renal cystic dysplasia and limb 
defects. Some of these phenotypes are consistent with defects in Wnt and Bmp signalling 
pathways, respectively (Grisaru et al., 2001; Paine-Saunders et al., 2000; Song et al., 2005). 
Additional studies have also shown that the developmental overgrowth observed in gpc3-
null mice is, at least in part, a consequence of the hyperactivation of the Hh pathway 
indicating that Gpc3 inhibits Hh ( Gallet et al., 2008; Capurro et al., 2009). Interestingly, 
Gpc5 stimulates the proliferation of rhabdomyosarcoma cells by eliciting a positive action 
on Hh signalling (Li et al., 2011), in contrast to the Gpc3-mediated negative control of Hh. 
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These findings reveal that members of the Gpc family can display opposite roles in the 
regulation of a given signalling protein. The C. elegans Gpc Lon-2 also controls body size 
length (Gumienny et al., 2007). It has been proposed that Lon-2 negatively regulates Bmp 
signalling as lon-2 mutants recapitulate phenotypes caused by Bmp over-expression 
(Gumienny et al., 2007). Another example is the Zebrafish knypek, which encodes the gpc 
homolog to mammalian Gpc4/Gpc6 (Topczewski et al., 2001). knypek controls convergent-
extension movements during zebrafish gastrulation by positively modulating Wnt11 
activity (Topczewski et al., 2001).  
Modulation of extra-cellular signals by Gpcs has also been reported in Xenopus. In 
particular, reducing Gpc4 (Xgly4) disrupts cell movements during gastrularion (Ohkawara 
et al., 2003). We have also shown that loss-of Gpc4 function in Xenopus embryos impairs 
forebrain patterning and cell survival from early neural plate stages onwards, and that these 
early developmental defects result in brains affected by microcephaly at later stages (Fig. 2; 
Galli et al., 2003). Xgly4 physically interacts with Wnt11, and might enhance function in the 
Wnt/PCP pathway during gastrulation (Ohkawara et al., 2003). In addition to Wnt11, we 
have demonstrated that Xgly4 also binds Fgf2. Inhibition of Fgf signalling results in dorsal 
forebrain phenotypes similar to those of Xgly4 depleted embryos, indicating that 
establishment and patterning of the dorsal forebrain territory may require modulation of Fgf 
signalling by Xgly4 (Galli et al., 2003).  
 
Fig. 2. Forebrain defects in GPC-4 depleted embryos. Side view of Xenopus embryos at tail 
bud stage showing expression of the dorsal forebrain marker emx-2 as detected by whole 
mount in situ hybridization (arrow in all panels). Xenopus embryos were injected at 2 cell 
stage with morpholino oligos to interfere with Gpc-4 activity. Injections were done by using 
control morpholino (controlMo), or morpholino targeting gpc-4 (gpc-4Mo). Embryos were 
also co-injected with morpholino targeting gpc4 (gpc-4Mo) and mouse gpc-4 mRNA (mgpc-4 
mRNA) for rescue experiments. (A, B) emx-2 expression in the dorsal forebrain of tailbud 
embryos; note the loss of emx-2 expression and the forebrain microcephalic morphology in 
GPC-4 depleted embryos (B). (C) Rescue of emx-2 expression and forebrain morphology in a 
tail bud embryo co-injected with Gpc-4Mo and mGpc-4 mRNA. Br: brain; Ta: Tail. 
In Drosophila the Gpc Dally-like is required for Hh signalling in the embryonic ectoderm 
whereas both Gpcs Dally and Dally-like are required and redundant in Hh movement in 
developing wing imaginal discs (Han et al., 2004; Yan and Lin, 2009). Additional studies on 
the wing disc patterning have also demonstrated that in Dally and Dally-like mutants the 
distribution and signalling of Wnt and Bmp family members, Wingless (Wg) and 
Decapentaplegic (Dpp) respectively, are altered (Nybakken and Perrimon, 2002). 
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Furthermore, Dally and Dally-like also act on Wg during segment polarity determination and 
on Dpp in the developing eye and antennal discs (Hacker et al., 2005; Lin, 2004). Overall, 
these and other studies reveal that different cell types can take advantage of Gpc-mediated 
regulation to control signal supply during distinct developmental processes. In addition, 
they show that vertebrate and invertebrate Gpcs have diverse and specialized functions 
towards a given signalling protein including their capability of enhancing or suppressing its 
activity in a stage- and/or tissue-specific regulated manner. 
3.2 Heparan sulphate chains and core proteins for signal control 
The findings that Gpcs enable cells controlling activity of a wide range of extracellular 
effectors with greater selectivity towards biological outcomes, suggest that Gpcs are rather 
dynamic proteins capable of employing various mechanisms to exert their regulatory effects 
in biological processes. One question that has arisen is whether these properties are 
conferred by their unique structural motifs. As discussed above, Gpcs are most likely 
globular proteins with HS chains at the carboxyl terminus. Of note, Chen and Lander have 
identified that the Gpc1 globular domain is a structural motif that potently influences HS 
substitutions (Chen and Lander, 2001). Moreover, it has been proposed that the physical 
constraint of HS attachment sites at the carboxyl terminus could result in proteins with HS 
chains in the proximity of the cell surface. These basic structural features, together with the 
known versatile conformation and orientation of HS functional groups, could prime Gpc HS 
modifications to a degree that facilitate their contacts with cell-membrane proteins (e.g. 
signalling receptors) while retaining specificity in binding modes (Tumova et al., 2000). The 
GPI-anchorage is yet another feature that makes Gpc proteins subject to distinct subcellular 
localization and intracellular trafficking processes as well as to release into the extracellular 
environment through shedding mechanisms involving distinct extracellular lipases 
(Chatterjee and Mayor, 2001; Payne et al., 2007). Gpcs trafficking and shedding can both 
lead to a gain of signal, down-regulation properties and cell non-autonomous activities (Yan 
and Lin, 2009). These issues are the subjects of intense investigation, and a growing body of 
data is being published on Gpc mechanism of action. In this paragraph we briefly 
summarize the current state of our knowledge related to HS-mediated Gpc activity. We 
focus more on studies showing that the core protein and its GPI anchor confer on Gpcs 
additional functional versatility. 
3.2.1 The heparan sulphate chains  
The hypothesis that functional Gpc properties are mediated by HS modifications was first 
evaluated for the Fgf/Fgf receptor axis as it is well established that Fgfs rely on the co-
receptor role of HSPGs for receptor binding and activation. As demonstrated by 
experiments performed mainly in cultured cells and in cell-free systems, Gpc HS 
modifications can catalyze binding of Fgfs to their receptors and boost receptor activation 
and its biological functions. For example, purified HS chains derived from Gpc-1, 
following protease-mediated digestion, augment the binding of Fgf-2 and Fgf-1 to Fgf 
receptor 1 to an extent that lower concentrations of ligands are needed for activation 
(Bonneh-Barkay et al., 1997b). Also, the Gpc-dependant Fgf binding and activation of 
receptors is nearly abolished when cells are treated with chlorate to inhibit Gpc 
sulfatation (Steinfeld et al., 1996). In this context, covalent cross-linking of Fgf-2 to cells 
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expressing its receptor demonstrates a putative Fgf-2/Fgf receptor complex when HS 
modified Gpcs are present in the same cell (Steinfeld et al., 1996). A conclusion that can be 
drawn from these studies is that cell-surface Gpcs by means of their HS modification can 
function as essential partners for the Fgf tyrosine kinase receptor. Potential mechanisms of 
action may include immobilizing of the ligand, increasing its local concentration, 
presenting it to a signalling receptor, or otherwise modifying the molecular encounters 
between ligands and receptors. The expected overall effect is thus enhancing receptor 
activation at low ligand concentrations. Interestingly, whereas Gpc-1 HS chains potentiate 
the biological activity of Fgf-1 they strongly inhibit Fgf-7 function (Berman et al., 1999; 
Bonneh-Barkay et al., 1997a). This suggests that HS chains can also act as a dual 
modulator of biological activities exerting both stimulatory and inhibitory effects 
depending on factors involved. More recently, experimental settings involving depletion 
of these sulphate groups both in vivo and in cultured cells have demonstrated that Gpcs 
HSs mediate interaction with additional HS binding proteins and impact their activity. 
This includes the binding and stimulation of Wg (the drosophila homolog of Wnt) 
signalling in the wing imaginal disc by Dally as well as the ability of human Gpc-5 to 
interact with Hh and enhance its growth promoting activity in rhabdomyosarcoma cells ( 
Yan and Lin, 2009; Li et al. , 2011, ). Interestingly, Dally HS chains are required in vivo to 
activate high-threshold but not low-threshold target genes of Dpp (Kirkpatrick et al., 
2006), suggesting that HSPG core proteins could serve distinct functions in low- versus 
high-threshold morphogenetic signalling.  
Recent studies have revealed that the co-receptor function of Gpcs can also provide a new 
paradigm of cell-cell communication. In the stem cell niche associated with germ cells the 
Gpc Dally is critical for making and maintaining the female germ cells (Hayashi et al., 
2009). However, in this stem cell niche, dally is expressed by the cap cells, which also 
produce the Dpp signalling molecule, but not in the receiving cells (germ cells), which 
instead express Dpp receptor (Hayashi et al., 2009). These findings have raised questions 
and interest about the underlying molecular mechanisms. Studies in cultured cells have 
provided evidence that Dally enhances Dpp signalling in trans through a contact-
dependent mechanism allowing the complementation of co-receptor-receptor complexes 
in adjacent cells (Dejima et al., 2011). Therefore, unlike typical co-receptor functions, Dally 
can serves as a trans co-receptor for Dpp when it has to enhance its signalling on 
neighboring cells. So far the mechanism for contact-dependent signalling has been mainly 
attributed to membrane-bound ligands and receptors such as Delta-Notch and Ephrins 
and their receptor tyrosine kinases (Hainaud et al., 2006). The fact that Gpcs act as trans 
activator partners establishes new strategies for crosstalk between adjacent cells during 
tissue assembly and maintenance.  
In conclusion, a common theme throughout all studies is that HS chains are responsible for 
different aspects of Gpc biology. By means of HS chains Gpcs sequester secreted soluble 
ligands and modulates their activity. As co-receptors and trans co-receptor, Gpcs modulate 
ligand-receptor encounters that can activate and inhibit cell proliferation, motility, and 
differentiation. Also HS side chains are not uniform and changes in the distribution of 
sulphate groups may affect ligand-binding properties and biological outcomes in a cell type-
specific manner. 
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3.2.2 The glypican core proteins 
The GPI anchor and the core protein are two additional structural motifs that impinge on 
functional versatility of Gpcs at different levels. Most insights have come from cell biological 
approaches undertaken to investigate how Gpcs affect Hh and Wg signalling and gradient 
formation.  
Concerning Wg, genetic analysis of Dally-like in the wing imaginal discs has highlighted a 
role for this Gpc in polarizing the Wg morphogenetic gradient. In the wing imaginal disc, 
Wg is secreted by a narrow strip of cells located at the dorsal–ventral boundary and 
spreads over a distance of up to 20 cell diameters. Wg first accumulates on the cell surface 
apical side in expressing cells to be then re-distributed to the basolateral membrane of 
receiving cells, where it is released in association with lipoprotein particles (Panakova et 
al., 2005; Strigini and Cohen, 2000). It has been proposed that polarizing Wg on the cell 
membrane allows the subsequent polarization of morphogen distribution within an 
epithelium, thus resulting in distinct tissue patterns (Marois et al., 2006). Therefore, one 
major question in the field is how Wg reaches the basolateral cell surface when it is 
secreted apically. Gallet and colleagues have investigated the subcellular localization of 
Dally-like in this cellular system and shown that Dally-like, which is apically targeted by 
means of its GPI anchor, undergoes internalization and redistribution to the basolateral 
membrane through a dynamin-dependent endocytosis (transcytosis; Fig. 3; Gallet et al., 
2008). Interestingly, Wg is no longer detected at the basolateral surface of cells away from 
the Wg source in mutant cells lacking Dally-like protein. Moreover, tethering Dally-like at 
the cell membrane (by replacing the GPI anchor with a trans-membrane domain) strongly 
stabilized Wg at the apical surface while decreasing the amount of Wg at the basolateral 
compartment (Gallet et al., 2008). Altogether, these findings support the view that Wg is 
secreted apically and it is then endocytosed with the help of Dally-like (Fig. 3). Once 
internalized, Dally-like targets Wg by transcytosis to the basolateral compartment, where it 
is stabilized and can then spread farther away in a polarized manner (Fig. 3); Gallet et al., 
2008). These findings also open the intriguing possibility that Dally-like-mediated 
basolateral polarization of Wg accounts for Wg activity in long-range signalling (Gallet et 
al., 2008). However, whether this mechanism underlies distinct Wg signalling activity 
remains a matter of debate (Williams et al.; Yan et al., 2009). 
In contrast to the Wg situation, GPI-mediated endocytosis of Gpcs appears directly implicated 
in modulating Hh signalling in a positive and negative manner. For example, Dally-like 
endocytosis from the cell surface catalyzes the internalization of Hh in flies. In this context, 
internalization of Hh occurs together with its receptor Patched (Fig. 4; Gallet et al., 2008). 
Removing Patched from the membrane alleviates the inhibition of the transmembrane protein 
Smoothened by Patched and enables Smoothened to activate Hh target genes (Fig. 4; Gallet  
et al., 2008). Complementary studies performed in mice have revealed that the mammalian 
Gpc-3, via its GPI-anchor, also mediates internalization of Shh (the vertebrate homolog of 
Hedgehog) and regulates its signalling, with however opposing outcomes. Indeed, through 
endocytosis Gpc-3 inhibits Shh activity rather than activating it as in flies (Fig. 4; Capurro et al., 
2008; Gallet et al., 2008). It has been proposed that Gpc-3 has high affinity for Shh and can, 
therefore, compete with Patched for Shh binding (Capurro et al., 2008). Upon binding, Gpc-3 
targets Shh to endocytic vesicles for degradation, thus leaving the unliganded Ptc at the cell 
surface, and free to inhibit Smoothened (Fig. 4; Capurro et al., 2008). This possibility is also 
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consistent with results showing that hyperactivation of Shh can in part explain the Simpson-
Golabi-Behmel overgrowth syndrome caused by loss-of-function mutations in Gpc-3, and with 
other experiments revealing an increased expression of Shh target genes in Gpc-3 deficient 
mice and mouse embryonic fibroblasts (Capurro et al., 2008). 
 
Fig. 3. The GPI anchor of Dally-like triggers Wg transcytosis. The GPI anchor of Dally-like is 
required for its apical targeting, subsequent internalization through dynamin-dependent 
endocytosis and relocalization to the basolateral compartment. It has been proposed that Wg 
is secreted apically and is then endocytosed with the help of Dally-like. Once internalized, 
Dally-like targets by transcytosis Wg to the basolateral compartment , where it is stabilized 
and can then spread farther away in a polarized manner (adapted from Dong Yan and 
Xinhua Lin 2008). 
Interestingly, the Gpc3 core protein (without HS chains) binds with high affinity to Shh in 
cultured cells independently of its HS chains, while it does not interact with Patched (Capurro 
et al., 2008). These findings raise the possibility that the Gpc core protein cooperate with the 
GPI motif to establish differences in Gpc binding properties of signalling molecules, which will 
in turn affect biological readout. Of note, Williams and colleagues found that the Dally-like 
core protein without HS chains substantially rescues lack of Hh signalling in Dally-like mutant 
embryos, demonstrating specific activity for this structural domain (Williams et al., 2010). 
Similarly, the core proteins of the mammalian Gpc-4 and -6, which are the closest relatives of 
Dally-like, allow full dose-dependent re-activation of Hh, in contrast to Gpc-2, -3 and -5 that 
have no activity (Williams et al., 2010). This configuration of sequence homology and 
functional conservation suggests that the two major Gpc subfamilies have evolved similar 
roles in Hh signalling control (see also above). Therefore, Gpc agonistic and antagonistic 
signalling activities should also be identifiable in the Gpc core protein.  
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Fig. 4. Opposing roles for Gpcs in Hh signalling. (A) In Drosophila wing discs, Dally-like 
promotes Hh signalling. The GPI anchor of Dally-like is required for its apical targeting and 
subsequent internalization through dynamin-dependent endocytosis. Dally-like endocytosis 
from the cell surface catalyzes the internalization of Hh in flies that occurs together with 
Patched (Ptc). Removing Ptc from the cell membrane alleviates the inhibition of the 
transmembrane protein Smoothened (Smo) by Patched and enables Smoothened to activate 
Hh target genes. (B) In mouse development, Gpc3 acts as an inhibitor of Hh signalling.  
The Gpc3 core binds Shh on the cell surface and compete with Patched for Shh binding. 
Upon binding, Gpc-3 targets Shh to endocytic vesicles for degradation, thus leaving the 
unliganded Ptc at the cell surface, and free to inhibit Smoothened (adapted from Dong Yan 
and Xinhua Lin 2008). 
To date, additional studies support the idea that the protein cores selectively impact on 
functions of distinct Gpcs. For example, as opposed to the positive role of Dally in Wg 
signalling (Lin and Perrimon, 1999), Dally-like shows biphasic activities: as repressor for Wg 
short-range signalling and as activator for long-range responsiveness. It has been proposed 
that the Dally-like core protein has high binding affinity for Wg (Yan et al., 2009), a property 
that allows Dally-like to bind and retain Wingless on the cell surface. Interestingly, ectopic 
expression of Dally-like inhibits activation of Wg targets. In contrast, increasing the 
expression of the Wg receptor Frizzled leads to their activation (Yan et al., 2009). These and 
other results suggest that the physiological role of Wg is linked to the cellular ratio between 
Dally-like and Frizzled (Yan et al., 2009). In other words, Dally-like binds and retains 
Wingless on the cell surface away from its receptor Frizzled. However, Dally-like can also 
facilitate Wg binding to Frizzled depending on the ratio of ligand, receptor and Dally-like. 
Although intriguing, these results arise additional question that need to be answered. For 
example, how different is the affinity of Dally and Dally-like core proteins for Wg? Do 
Dally-like related mammalian Gpcs show dual roles in Wg modulation? Is there any specific 
protein domain required for Wg binding? Concerning the latter question, it has been proposed 
that Wg binding could occur via the N-terminal domain of Dally-like (Yan et al., 2009). 
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Moreover, structural analysis combined with structure-guided mutagenesis also suggests that 
this domain could guide Dally-like/Shh interaction (Kim et al., 2011). Further studies will 
address whether and in which manner the N-terminal domain impacts Gpc activity. 
In conclusion, the studies above discussed begin to unravel how Gpcs fulfil diverse 
functions in signalling pathways during development. In particular, they highlight the 
importance of GPI-mediated Gpc endocytosis in participating at the control of Wingless 
intracellular trafficking and possibly gradient formation, and in the modulation of Hh 
signalling in different biological context. Other important findings are the demonstration 
that Gpcs core proteins show binding affinity for certain signals independent of HS-side 
chains, and that they can modulate events as opposed as signal activation and inhibition. 
Thus, core proteins of Gpcs appear to ensure on its own an additional degree of signal 
modulation that increases specificity of biological readouts. 
4. Glypicans in human diseases 
Genome-wide linkage scan and mutation analysis have revealed that alteration in GPC 
functions can underlie human congenital malformation compromising developmental 
events such as bone growth and heart pattern formation. This discovery has permitted a 
better comprehension of pathophysiology of these disorders, their diagnosis and 
management. The generation of animal models has significantly broadened the 
understanding of these distinct developmental processes and their molecular bases.  
4.1 The Simpson-Golabi-Behmel Syndrome 
The Simpson-Golabi-Behmel Syndrome is an X-linked overgrowth disorder characterized by 
pre- and postnatal overgrowth, minor facial anomalies, skeletal defects, polydactyly and 
fingernail hypoplasia, small bulge in the small intestine, umbilical or inguinal hernia, 
genitourinary abnormalities, heart defects, supernumerary nipples and an increased risk of 
neonatal death (Gurrieri et al. , 2011). In patients there is also an increased risk of embryonal 
tumour development, mainly Wilms’ tumour. Mental retardation is not constantly found 
and is usually mild (Gurrieri et al. , 2011).  
Pilia and colleagues uncovered the genetic bases of this disorder in 1996 with the 
demonstration that mutations in the Gpc-3 gene are responsible for a large proportion of 
Simpson-Golabi-Behmel Syndrome cases. Since then, different Gpc-3 mutations have been 
identified in patients and these were found to be rather heterogeneous ranging from large 
chromosomal rearrangements to micro deletions and point mutations in different exons 
(Gurrieri et al. , 2011; Hughes-Benzie et al., 1996; Pilia et al., 1996; Sakazume et al., 2007; 
Xuan et al., 1999). Sequence analysis of mutated loci, led to the proposal that Simpson-
Golabi-Behmel Syndrome is caused by a non-functional GPC-3 protein while additional 
unknown genetic factors were possibly responsible for the phenotypic variations among 
patients. The role of GPC-3 in this disorder was then confirmed by the generation of Gpc-3-
deficient mice, since these mice recapitulate several phenotypes of the Simpson-Golabi-
Behmel Syndrome patients including developmental outgrowth and dysplastic kidneys 
(Cano-Gauci et al., 1999; Paine-Saunders et al., 2000). Moreover, recent findings showing 
that GPC3 polymorphisms have a significant impact in the body size of mice have provided 
additional support for a role of GPC3 in the regulation of body size (Oliver et al., 2005).  
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At a cellular level the tissue overgrowth syndrome of Gpc-3-deficient mice appears to be a 
consequence of an increased proliferation rate, which is consistent with the possibility that 
Gpc-3 acts as a negative regulator of cell proliferation in the mouse embryo (Hartwig et al., 
2005). However, Gpc-3 can also induce apoptosis in a cell-type specific manner suggesting 
that enhanced cell survival may also contribute to the overgrowth defects (Filmus, 2001), 
Interestingly, Simpson-Golabi-Behmel Syndrome patients develop embryonal tumours (see 
above). Moreover, Gpc-3 expression is markedly decreased in human gastric cancer. 
Therefore, it is likely that in humans Gpc-3 functions also as a tumour suppressor gene 
(Gonzalez et al., 1998).  
One of the current major challenges is to identify the GPC-3 targets relevant for the 
pathogenesis of this complex disease. It has been proposed that GPC-3 inhibits embryonic 
growth by negatively regulating Insulin-like growth factor-II (Pilia et al., 1996). However, 
studies in cultured cells have failed to detect any biochemical or genetic interaction between 
Gpc-3 and the Insulin-like growth factor-II signalling pathway (Cano-Gauci et al., 1999; 
Chiao et al., 2002; Song et al., 2005). Capurro and colleagues explored the possibility that 
Gpc-3 acts as a negative regulator of body size by inhibiting two mammalian Hh proteins: 
Shh and Indian Hh (see also above; Capurro et al., 2008; Capurro et al., 2009). The rational 
behind this approach is linked to findings revealing that 1) these two Hh family members 
are both present in the developing embryo, with Shh more widely expressed and Indian Hh 
restricted to the developing bones; 2) hyperactivation of the Hh signalling pathway in mice 
causes overgrowth phenotypes (Makino et al., 2001; Milenkovic et al., 1999); 3) in humans, 
Patched mutations are linked to Gorlin’s Syndrome, a disorder causing multiple 
basocellular carcinomas accompanied by large head size, longer-larger bones, and 
polydactyly (Hahn et al., 1996). As discussed above, secreted Hh proteins binds and 
antagonizes the function of the Patched receptor known to block the activity of the 
signalling effector Smoothened. Binding of Hhs to Patched thus results in the activation of 
Smoothened, which in turn transduces the Hh signal intracellularly leading to the activation 
of Hh target genes such as Gli and Patched (Hooper and Scott, 2005). In a first study, 
Capurro and colleagues compared the degree of activation of the Hh signalling pathway in 
gpc-3 null mouse embryos and culture cells as well as potential Gpc-3/Shh protein 
interaction (Capurro et al., 2008). Results showed that the levels of Shh protein and of its 
targets increases in structures affected by Simpson-Golabi-Behmel Syndrome (e.g. gut and 
digits). As discussed above, they also uncovered that Gpc-3 can bind Shh and activate its 
signalling pathway, and acts as a competitive inhibitor of the Shh-Patched interaction, and 
triggers Shh endocytosis and degradation (Capurro et al., 2008). Therefore, a reasonable 
picture that can be drawn from these studies is that Gpc-3 normally restrains Hh signalling 
to control body size. Lack of Gpc-3 leads to the hyperactivation of this pathway causing the 
overgrowth phenotype of the Simpson-Golabi-Behmel Syndrome patients (Capurro et al., 
2008). 
To provide further genetic evidence that the Hh signalling pathway mediates, at least in 
part, the regulatory activity of Gpc-3 on embryonic growth, Capurro and colleagues 
performed a second study where they attempted to rescue the overgrowth phenotype of 
Gpc-3 deficient embryos by crossing them with mice carrying an Indian Hh null allele 
(Capurro et al., 2009). Indian Hh was chosen because its activity is more confined to 
endochondral skeleton. Indeed, Indian Hh deficient mice show a severe growth deficiency 
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in the endochondral skeleton as a result of a reduced chondrocyte proliferation and 
maturation, as well as osteoblast formation (St-Jacques et al., 1999). In contrast, Viviano and 
colleagues reported an abnormal persistence of hypertrophic chondrocytes in Gpc-3-
deficient embryonic bones and a delay in endochondral ossification (Viviano et al., 2005). As 
for Shh, Gpc-3 deficient mice show more Indian Hh and Patched protein levels in the 
developing long bones (Capurro et al., 2009). Moreover the overgrowth syndrome of Gpc-3 
deficient mice is partially rescued in the Indian Hh null background (Capurro et al., 2009). 
Therefore, the author proposed that the accumulation of Indian Hh as a result of the lack of 
Gpc-3 might be the cause of an unbalance rate of chondrocyte proliferation versus 
differentiation, which ultimately causes the longer bone overgrowth found in mutant mice 
(Capurro et al., 2009; Viviano et al., 2005). Although further investigations will elucidate 
how lack of Gpc-3 affects development at the cellular level, these genetic studies provide 
important clues on the molecular basis of Simpson-Golabi-Behmel Syndrome in humans by 
beginning to unravel the aberrant signalling mechanisms. Moreover, they have also told us 
that more broad approaches such as tissue micro-arrays need to be taken into account to 
understand this complex disorder. In this context, the gpc-3-deficient mouse model will be 
instrumental to identify and evaluate the involvement of other signalling pathways as well 
as to determine whether Gpc-3 has tissue specific effects in this disease. Of note, there are 
the studies on the gpc-3-deficient mice indicating that an impairment of the Fgf/Shh 
signalling axis in the embryonic hearts could underlie the congenital cardiac malformations 
in Simpson-Golabi-Behmel syndrome (St-Jacques et al., 1999) while the renal dysplasia 
could be linked to an inbalance of stimulatory and inhibitory signals (e.g. Fgf-7 and Bmp-2 
respectively) during tissue morphogenesis (Grisaru et al., 2001).  
Further help in understanding the involvement of Gpc-3 in this human disorder could come 
from attempts to define structural-functional relationships associated with specific Gpc-3 
mutations in humans. Interestingly, one Simpson-Golabi-Behmel Syndrome patient has a 
deletion affecting both Gpc-3 and Gpc-4, which is found immediately centromeric to Gpc-3 at 
Xq26 (Veugelers et al., 1998). Recently, a wide screening has identified patients carrying 
mutations in the Gpc-4 but not in the Gpc-3 gene (Waterson et al., 2010). We anticipate that 
future research will extensively evaluate whether connections between GPC-4 functions and 
the clinical features of this syndrome exist.  
4.2 Autosomal-recessive omodysplasia 
Autosomal recessive omodysplasia is a genetic condition characterized by skeletal and 
craniofacial defects (Maroteaux et al., 1989). Skeletal abnormalities include shortening and 
distal tapering of the humerus and femur, proximal radioulnar diastasis, and anterolateral 
radial head dislocation. In patients with autosomal recessive omodysplasia both upper and 
lower limbs are affected in contrast to the dominant form of the disorder in which the lower 
limbs are normal. Facial defects comprise frontal bossing, a flat nasal bridge, low set ears, a 
long philtrum, anteverted nostrils, and frontal capillary hemangiomas. Variable findings are 
hernias, congenital heart defects, mental retardation and delayed motor development. Being 
recessive, autosomal recessive omodysplasia is a rare disorder with an incidence of <1 / 
1000000 and, to date, around 22 cases of recessive omodysplasia have been described. 
Recent advances in understanding its pathophysiology have come from Campos-Xavier and 
collaborators reporting that the autosomal-recessive omodysplasia maps to chromosome 13 
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(13q31.1-q32.2; (Campos-Xavier et al., 2009). By performing fine analysis of candidate genes, 
Campos-Xavier and collaborators have further linked autosomal recessive omodysplasia to 
point mutations or to larger genomic rearrangements in the Gpc-6 gene (Campos-Xavier et 
al., 2009).  
All mutations found in the individuals affected by omodysplasia predict absence of a 
functional protein. Hypothetical mutant proteins would be truncated and thereby lose both 
the GPI and the HS-binding sites, essential for the putative GPC-6 functions (Campos-Xavier 
et al., 2009). Similarly to Gpc-3, Gpc-6 mutations are also found in the entire coding region 
without any mutational hotspot and include one or more exons. Recently, Gpc-5 
haploinsufficiency has been proposed as the molecular cause of upper limb anomalies and 
growth retardation in 13q deletion syndrome because of its expression in the developing 
limb (Quelin et al., 2009). Gpc-5 colocalises with Gpc-6 on 13q31.2–q31.3, and the two genes 
are clustered, similarly to Gpc-3 and Gpc-4 on chromosome X, suggesting that these 
members of the Gpc family share an evolutionary link (see also above; Filmus, 2001) that 
might reflect a common function (De Cat and David, 2001; Paine-Saunders et al., 2002; see 
also above). However, because GPC-5 does not compensate for loss of GPC-6 in 
omodysplasia patients, their functional relationship is not supported. 
Axial bone growth occurs through growth plates in which chondrocytes undergo 
proliferation, hypertrophy, cell death, and osteoblastic replacement (Ornitz and Marie, 
2002). The immature chondrocytes are rapidly proliferating cells characterized by a small 
size and irregular shape. In the hypertrophic cartilage zone, chondrocytes make matrix and 
enlarged lacunae. The pathological characteristics of the omodysplastic growth plates are an 
expanded zone of proliferating cartilage and an increased number of closely packed, small 
chondrocytes suggesting that omodysplasia is due to an impaired endochondral ossification 
(Borochowitz et al., 1998). During endochondral ossification, Gpc-6 is predominanlty 
expressed in the proliferative zone decreasing dramatically in the prehypertrophic and 
hypertrophic zones (Campos-Xavier et al., 2009). These expression data correlate with the 
morphologic findings in the human omodysplasia. They also correlate with the distribution 
of Indian Hh, Fgf, Bmp and Wnt proteins, which are known to regulate endochondral 
ossification (Ornitz and Marie, 2002) and to have the potential of functionally interacting 
with Gpc-6. Moreover, the etiology of many other human skeletal dysplasias with defects in 
endochondral ossification has been attributed to specific mutations in the gene encoding 
FGF receptor 3 (Ornitz and Marie, 2002). The international mouse strain resource (IMSR ; 
http://www.findmice.org/) has recently generated different mouse strains carrying loss of 
function mutations in the gpc-6 gene but to our knowledge, no studies have been yet 
reported. The functional analysis of gpc-6 mutant mice will be crucial to establish the 
involvement of Gpc-6 functions in this disorder and to uncover the cellular and molecular 
basis of all associated clinical features.  
5. Conclusion and future direction 
Research over the past years has advanced our understanding of Gpc functions during 
mammalian development and the list of human syndromes associated with their aberrant 
function is likely to grow. Indeed, recent studies have described Gpc-5 and Gpc-6 as 
candidate genes for postaxial polydactyly type A, an inherited human condition causing 
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digit duplications (van der Zwaag et al. , 2010). Gpc genes have also been linked to other 
less defined human diseases, such bipolar disorder and Sudden Cardiac Arrest (Arking et 
al. 2011; Maheshwari et al., 2002) and further studies will clarify their involvement. We and 
others have shown that Gpcs are among the most abundant HSPGs in the developing 
nervous system and are expressed in embryonic and adult neural stem cells (Bandtlow and 
Zimmermann, 2000; Hagihara et al., 2000; Luxardi et al., 2007). Our embryological 
manipulations in Xenopus embryos have begun to provide insight into their role in brain size 
as abrogation of Gpc4 activity in Xenopus embryos disrupts forebrain patterning and cell 
survival, and causes microcephaly (see also above and Ficure 2; Galli et al., 2003). Therefore, 
our findings raise the possibility that some of the congenital microcephalies may arise as a 
consequence of disrupting Glpc-4 gene function during brain development.  
As discussed above, Gpc genes are inclined to cluster on the same chromosome. Simpson-
Golabi-Behmel patients can carry deletions that affect not only the Gpc-3 but also the Gpc-4 
gene. In mouse, gpc-3 shows distinct expression patterns compared to gpc-4 and the latter is 
highly expressed in the developing brain and kidney (Luxardi et al., 2007). Therefore, it is 
possible that mutation in the Gpc-4 gene also contribute to aspects of the Simpson-Golabi-
Behmel syndrome. Further studies will require the analysis of gpc compound mutant 
embryos and mice as they could recapitulates additional clinical features of this syndrome.  
A second major area of research will concern the identification of the pathological signalling 
events underlying the clinical features of disorders associated with abnormal GPC 
functions. When analysing pathologies involving GPC, it is important to take into account 
that these diseases might be also linked to GPC gain-of-functions rather then loss-of-
functions. The gene targeting approach in mice has begun to clarify this issue. As described 
above, Gpcs control different signalling proteins in a cell-type and developmental-stage 
specific manner. Therefore, further studies will require tissue- and stage-specific loss-of-
function mutations of gpc genes. We think that a better understanding of Gpc involvement 
in normal and pathological processes, as well as the identification of the associated signals 
can hopefully provide a wider clinical spectrum for the development of targeted therapies. 
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